Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System

Adverse event reports submitted to the US Food and Drug Administration (FDA) were analyzed to map the safety profile of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). We conducted a disproportionality analysis of the adverse events (AEs) of EGFR-TKIs (gefitinib, erlotinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jing, Meng, Long, Yang, Bing, Sun, Shusen, Luo, Zhigang, Chen, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075865/
https://www.ncbi.nlm.nih.gov/pubmed/32179761
http://dx.doi.org/10.1038/s41598-020-61571-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075865/
https://www.ncbi.nlm.nih.gov/pubmed/32179761
http://dx.doi.org/10.1038/s41598-020-61571-5

Ejemplares similares